期刊
EPIGENOMICS
卷 8, 期 1, 页码 119-133出版社
FUTURE MEDICINE LTD
DOI: 10.2217/epi.15.84
关键词
DNA methylation; epigenome; histone modification; personalized medicine; targeted therapy
资金
- National Basic Research Program of China (973 Program) [2012CB934002, 2015CB553904]
- National High-tech R&D Program of China (863 Program) [SS2012AA020314, SS2012AA020821, SS2012AA020303]
- National Key Scientific instrument Special Programme of China [2011YQ03013405]
- National Science Foundation of China [81490753]
Cancer genome sequencing has created an opportunity for precision medicine. Thus far, genetic alterations can only be used to guide treatment for small subsets of certain cancer types with these key alterations. Similar to mutations, epigenetic events are equally suitable for personalized medicine. DNA methylation alterations have been used to identify tumor-specific drug responsive markers. Methylation of MGMT sensitizes gliomas to alkylating agents is an example of epigenetic personalized medicine. Recent studies have revealed that 5-azacytidine and decitabine show activity in myelodysplasia, lung and other cancers. There are currently at least 20 kinds of histone deacetylase inhibitors in clinical testing. Inhibitors targeting other epigenetic regulators are being clinically tested, such as EZH2 inhibitor EPZ-6438.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据